Business Description
Atea Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
ISIN : US04683R1068
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 248.01 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -56.7 | |||||
3-Year EPS without NRI Growth Rate | -47.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 33.89 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.3 | |||||
9-Day RSI | 33.63 | |||||
14-Day RSI | 38.98 | |||||
6-1 Month Momentum % | -4 | |||||
12-1 Month Momentum % | 24.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 19.02 | |||||
Quick Ratio | 19.02 | |||||
Cash Ratio | 18.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 0.25 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -32.35 | |||||
ROA % | -30.42 | |||||
ROIC % | -3865.82 | |||||
3-Year ROIIC % | 52.11 | |||||
ROC (Joel Greenblatt) % | -6551.1 | |||||
ROCE % | -37.01 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.61 | |||||
Price-to-Tangible-Book | 0.61 | |||||
EV-to-EBIT | 1.03 | |||||
EV-to-EBITDA | 1.03 | |||||
EV-to-FCF | 1.73 | |||||
Price-to-Net-Current-Asset-Value | 0.61 | |||||
Price-to-Net-Cash | 0.62 | |||||
Earnings Yield (Greenblatt) % | 97.09 | |||||
FCF Yield % | -41.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVIR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Atea Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.1 | ||
Beta | 0.4 | ||
Volatility % | 46.62 | ||
14-Day RSI | 38.98 | ||
14-Day ATR ($) | 0.161658 | ||
20-Day SMA ($) | 3.6785 | ||
12-1 Month Momentum % | 24.68 | ||
52-Week Range ($) | 2.765 - 4.6 | ||
Shares Outstanding (Mil) | 84.42 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Atea Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Atea Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Atea Pharmaceuticals Inc Frequently Asked Questions
What is Atea Pharmaceuticals Inc(AVIR)'s stock price today?
When is next earnings date of Atea Pharmaceuticals Inc(AVIR)?
Does Atea Pharmaceuticals Inc(AVIR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |